Search research articles
Contact Us
Filters
Showing results (51-60 of 71) with videos related to
Page
of 8
Sort By:
Urologic Oncology
|
April 25, 2022
Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT)
Arsalan Tariq, Stephen McGeorge, Adam Pearce, et al.
European Urology Focus
|
January 9, 2024
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging of Selected Renal Tumours: Initial Experience in a Multicentre Cohort
Arsalan Tariq, Adam Pearce, Handoo Rhee, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 17, 2023
Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management
Shivanshan Pathmanathan, Arsalan Tariq, Adam Pearce, et al.
Neuroendocrinology
|
September 1, 2022
Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide Therapy
Minmin Li, David L Chan, Gonzalo Tapia Rico, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 17, 2018
<sup>64</sup>Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy
Rodney J Hicks, Price Jackson, Grace Kong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 17, 2019
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
John Violet, Shahneen Sandhu, Amir Iravani, et al.
Nature Cancer
|
April 15, 2026
Predictive value of early PSMA upregulation for the response to enzalutamide ± <sup>177</sup>Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial
Louise Emmett, Mina Swiha, Nathan Papa, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 16, 2026
[<sup>177</sup>Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial
David L Chan, Katrin Marie Sjoquist, David Turner Ransom, et al.
The Lancet. Oncology
|
August 2, 2025
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
Louise Emmett, Nathan Papa, Shalini Subramaniam, et al.
The Lancet. Oncology
|
September 18, 2024
Sequential [<sup>177</sup>Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
Arun A Azad, Mathias Bressel, Hsiang Tan, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 71) with videos related to
Sort By:
Page
of 8
Urologic Oncology
|
April 25, 2022
Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT)
Arsalan Tariq, Stephen McGeorge, Adam Pearce, et al.
European Urology Focus
|
January 9, 2024
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging of Selected Renal Tumours: Initial Experience in a Multicentre Cohort
Arsalan Tariq, Adam Pearce, Handoo Rhee, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 17, 2023
Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management
Shivanshan Pathmanathan, Arsalan Tariq, Adam Pearce, et al.
Neuroendocrinology
|
September 1, 2022
Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide Therapy
Minmin Li, David L Chan, Gonzalo Tapia Rico, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 17, 2018
<sup>64</sup>Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy
Rodney J Hicks, Price Jackson, Grace Kong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 17, 2019
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
John Violet, Shahneen Sandhu, Amir Iravani, et al.
Nature Cancer
|
April 15, 2026
Predictive value of early PSMA upregulation for the response to enzalutamide ± <sup>177</sup>Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial
Louise Emmett, Mina Swiha, Nathan Papa, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 16, 2026
[<sup>177</sup>Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial
David L Chan, Katrin Marie Sjoquist, David Turner Ransom, et al.
The Lancet. Oncology
|
August 2, 2025
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
Louise Emmett, Nathan Papa, Shalini Subramaniam, et al.
The Lancet. Oncology
|
September 18, 2024
Sequential [<sup>177</sup>Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
Arun A Azad, Mathias Bressel, Hsiang Tan, et al.
Page
of 8